Temperature and humidity stability testing is fundamental to understanding how environmental conditions affect drug stability and ensuring pharmaceutical products remain safe, effective, and high quality throughout their shelf life.

In pharmaceutical development, even small changes in environmental conditions can have significant consequences. Stability testing, particularly under controlled temperature and humidity provides critical insight into how drugs degrade over time, how they should be stored, and how long they can be used safely. This is not just a regulatory requirement; it’s a scientific necessity that underpins product integrity and patient safety.

Why Temperature Matters in Drug Stability:

Temperature is one of the most influential factors affecting drug stability. As temperature increases, molecular activity accelerates, which in turn speeds up chemical reactions. This often leads to faster degradation of pharmaceutical products.

At elevated temperatures:

• Chemical bonds break more quickly
• Degradation pathways are accelerated
• Physical changes, such as discoloration, may occur

This is why products stored outside their recommended temperature range may lose potency or become unsafe. Even short-term exposure to higher temperatures, known as temperature excursions can have cumulative effects, especially in sensitive formulations like biologics.Pharmaceutical Stability Testing: Why it Matters in Drug Development

The Impact of Humidity of Pharmaceutical Products:

Humidity can also contribute to degradation of pharmaceutical products, this can be both physical and chemical effects. Humidity can cause moisture uptake, which leads to physical degradation, accelerated chemical breakdown(hydrolysis) and altered drug release rates.

One major process is hydrolysis (where molecules react with pharma products, breaking down their structure and sometimes creating by-products) which can fundamentally change the drugs structure, leading to the formation of toxic by-products.

High humidity, especially above, 60% results in a higher possibility of microbial growth, including bacteria, mold and fungi.

Humidity also speeds up oxidation, which can reduce potency and change the appearance of materials. Many active pharmaceutical ingredients (APIs) are hygroscopic, meaning they absorb moisture. This can cause powders to clump, making them harder to handle and dose accurately.

Stability testing storage helps to reduce the possibility of hydrolysis and microbial growth by determining how pharmaceutical products react under certain temperature and humidity, aiding in the process to determine shelf life of the drugs while seeing if they are suitable for that specific stability zone.

Standard ICH Stability Conditions:

The world is split into different stability zones, which are dependant on the temperature and humidity of a region.

These stability zones are used to align stability testing conditions with global environmental variations, ensuring pharmaceutical products are tested under conditions that reflect their intended market.

The ICH guidelines are harmonised standards that protects the rights, safety and welfare of human subjects eliminating exposure to investigational products, improve the quality of data, and speed up the marketing of new drugs.

Some of the most popular ICH conditions pharmaceutical companies need to test their products and packaging in include:

• 25°C/60%rh – long-term study climate zone 1 and 2
• 30°C/65%rh – intermediate study
• 30°C/75%rh – Long term study climate zone 4
• 40°C/75%rh – Accelerated stability study

These standardised conditions allow for reliable comparison of stability data and support global regulatory submissions.

Environmental Stability in Biologics:

In biologics, environmental stability is closely tied to the inherent sensitivity of proteins to temperature and humidity. Even under controlled conditions, these factors can drive subtle but meaningful degradation pathways that impact product quality.

Proteins are not fully stable even within standard storage ranges (e.g, 2-8°C or 25°C). Small temperatures variations can shift protein structure, increasing the likelihood of partial unfolding, this exposes hydrophobic regions and promotes aggregation, one of the most critical risks in biologics.

Temperature also accelerates chemical degradation, including deamidation and oxidation. These changes can alter protein structure, reduce potency, and increase heterogeneity. Importantly, even brief temperature excursions can have cumulative effects, reinforcing the need for tight control and well-defined excursion limits in stability programs.

Humidity is particularly important for lyophilized and solid-state formulations. Moisture uptake increases molecular mobility, enabling degradation reactions such as hydrolysis. It can also compromise physical stability, leading to cake collapse or slower reconstitution.

In liquid biologics, humidity can influence stability indirectly through packaging interactions, such as moisture ingress or changes in headspace conditions. Over time, this can affect concentration, pH, and overall protein stability.

Effective stability testing must account for both temperature and humidity stress. While accelerated conditions help identify degradation pathways, real-time studies remain essential.

Controlled Ambient vs Accelerated Conditions:

At controlled ambient conditions (typically 25 °C/60% RH), biologics are exposed to higher thermal and humidity stress than refrigerated storage, leading to increased protein mobility and a greater risk of gradual degradation. Even within these limits, proteins can undergo partial unfolding, aggregation, or chemical modifications such as oxidation and deamidation, which may impact potency and product heterogeneity over time. These studies are especially important for products intended for room-temperature storage, as they reflect more realistic handling and distribution conditions.

Accelerated conditions (commonly 40 °C/75% RH) further amplify these effects, driving faster degradation and helping to identify stability risks early in development. Elevated humidity can also play a critical role, particularly for lyophilized formulations where moisture uptake increases molecular mobility and promotes degradation pathways like hydrolysis. While accelerated data are valuable for understanding degradation mechanisms and informing formulation or packaging decisions, they must be interpreted carefully, as they do not always directly predict real-time stability.

Why precise environmental control is critical across pharma and life sciences:

In the pharmaceutical and life sciences sectors, precise environmental control is not just a technical requirement it is foundational to product integrity, regulatory compliance, and ultimately patient safety. Stability testing depends on tightly controlled temperature and humidity conditions to generate reliable, reproducible data that accurately reflects how a product will perform over time. Even minor deviations can alter degradation pathways, impact efficacy, or mask potential risks, leading to costly delays or regulatory challenges. Beyond compliance with ICH guidelines, maintaining environmental precision ensures confidence in every stage of development, from formulation through to market release. As products become more complex and global supply chains more demanding, the ability to consistently control and monitor environmental conditions is no longer optional it is a critical enabler of quality, trust, and innovation across the industry.